What Iron Level Requires an Iron Infusion?

There is no single iron level that automatically triggers an infusion. The decision depends on a combination of lab values, your underlying health conditions, how severe your symptoms are, and whether oral iron supplements have failed or are unlikely to work. In straightforward cases of iron deficiency without complicating illness, ferritin below about 30 µg/L is the standard diagnostic cutoff, and most doctors will try oral iron first. But in people with chronic inflammatory diseases, the thresholds shift dramatically, and the route to an infusion shortens.

Why There Is No Single Number

Ferritin, the blood test most people associate with iron status, measures stored iron. In a person without significant inflammation, a ferritin below 30 µg/L reliably signals iron deficiency, and some guidelines for women with heavy periods use a cutoff as low as 15 µg/L. But ferritin is also what’s called an acute-phase reactant: your body pumps out more of it when you’re fighting infection, dealing with chronic disease, or carrying widespread inflammation. That means someone with Crohn’s disease, heart failure, or kidney disease can have a “normal-looking” ferritin of 80 or even 200 µg/L and still be profoundly iron-deficient.

This is why doctors rely on more than one number. Transferrin saturation (TSAT) measures how much iron is actually circulating and available for your body to use right now, rather than how much is locked away in storage. When ferritin looks reassuringly normal but TSAT drops below 20%, that’s a red flag that iron isn’t getting where it needs to go. In inflammatory conditions such as heart failure, chronic kidney disease, and inflammatory bowel disease, a ferritin below 100 µg/L or a TSAT under 20% is generally considered diagnostic for iron deficiency, even though those numbers would look fine in a healthy person.¹ When ferritin sits between 100 and 300 µg/L, confirming iron deficiency requires a TSAT below 20%.

The Hepcidin Problem and Why Oral Iron Fails

Understanding why infusions exist at all requires knowing about hepcidin, a hormone your liver produces that acts as the master gatekeeper for iron absorption. When hepcidin levels are high, your gut essentially locks the door on incoming iron. You can swallow as many iron tablets as you like, and very little will get through. Two things reliably drive hepcidin up: having plenty of iron already on board (which is the body’s way of preventing overload) and inflammation.² The inflammatory signal interleukin-6, which is elevated in conditions ranging from rheumatoid arthritis to heart failure, directly stimulates hepcidin production.³

This creates a frustrating paradox for patients with chronic illness: the very inflammation causing their iron deficiency also prevents them from absorbing oral iron. Intravenous iron sidesteps hepcidin entirely because it goes straight into the bloodstream, bypassing the gut. That’s the core biological rationale for infusions, and it explains why certain patient groups are fast-tracked to IV iron rather than being asked to try pills for months first.

Heart Failure

Heart failure guidelines have historically defined iron deficiency as ferritin below 100 ng/mL, or ferritin between 100 and 299 ng/mL with a TSAT under 20%.⁴ Meeting either criterion in the context of symptomatic heart failure has traditionally been enough to justify an iron infusion, because oral iron is poorly absorbed in these patients and clinical trials have shown improvements in exercise tolerance and hospitalization rates after IV iron.

That said, the field is actively reconsidering these cutoffs. A recent analysis in Circulation argued that the ferritin-based definition captures too many patients who aren’t actually iron-deficient, including those with ferritin levels in the normal range of 20 to 100 µg/L who have adequate TSAT, a good prognosis, and no meaningful response to iron therapy. The proposed alternative is simpler: define iron deficiency in heart failure purely by TSAT below 20%. Patients meeting that criterion tend to show true iron depletion on bone marrow examination and experience a roughly 20 to 30 percent reduction in cardiovascular death or heart failure hospitalizations after IV iron.⁵ If your cardiologist is discussing iron infusions with you, TSAT is likely a bigger part of the conversation than ferritin alone.

Inflammatory Bowel Disease

People with Crohn’s disease or ulcerative colitis face a double hit: chronic intestinal inflammation both blocks iron absorption and causes ongoing blood loss from the gut. Standard ferritin thresholds miss many of these patients. Research on ulcerative colitis found that when inflammation is relatively low (CRP under 10 mg/L), a ferritin of 65 µg/L and TSAT of 16% offered the best balance of sensitivity and specificity for detecting iron deficiency. When inflammation is higher, the optimal ferritin cutoff rises to around 80 µg/L.⁶

Once iron deficiency is confirmed in IBD, there’s a strong case for going straight to infusions. A meta-analysis of randomized trials found that IV iron was more effective than oral iron at raising hemoglobin by at least 2.0 g/dL, and patients were far less likely to discontinue treatment. The gastrointestinal side effects that make oral iron miserable for many IBD patients, including nausea, cramping, and worsening of gut symptoms, were consistently lower in the IV groups.⁷ For many gastroenterologists, IV iron is the default rather than the backup in this population.

Pregnancy

Iron demands surge during pregnancy, and iron deficiency anemia is common, especially in the second and third trimesters. Most pregnant individuals start with oral iron, but when pills cause intolerable side effects or hemoglobin doesn’t respond adequately, IV iron becomes the next step. Safety data support the use of newer IV iron formulations in the second and third trimesters, though IV iron is generally avoided in the first trimester due to limited safety information from that period.⁸

A meta-analysis of 19 studies comparing IV to oral iron in pregnancy found that at four to six weeks after treatment, IV iron raised hemoglobin by an average of about 0.6 g/dL more than oral iron and boosted ferritin by roughly 73 ng/mL more.⁹ A cost-effectiveness study from India found that IV iron raised hemoglobin from about 8.2 g/dL to 11.5 g/dL over the course of follow-up, while the oral iron group’s hemoglobin actually drifted downward slightly. Side effects were reported by about 60% of women on oral iron, compared with roughly 11% on IV iron.¹⁰ The incremental cost was modest relative to the benefit, but access to infusion facilities remains a practical barrier in many settings.

Before Surgery and After Heavy Blood Loss

Preoperative iron infusions have become a growing part of what’s called patient blood management, the idea being that going into surgery with higher hemoglobin reduces the need for blood transfusions. Several clinical guidelines recommend IV iron as a first-line option when surgery is imminent and there isn’t time for oral iron to work, or when hemoglobin is at or below 9 g/dL.¹¹

Timing matters a great deal. One study found that hemoglobin barely budged when IV iron was given fewer than six days before surgery, but climbed by about 1.75 g/dL when given 16 days out.¹² A separate retrospective study confirmed that only a minimal hemoglobin increase was observed when infusions were given less than two weeks before the operating date.¹³ So if you’re told you need IV iron before a scheduled procedure, earlier is better. A week before surgery is cutting it close; two to three weeks gives the body enough time to manufacture new red blood cells with that iron.

For women with heavy menstrual bleeding, the path to an infusion often follows repeated cycles of oral iron that don’t keep up with monthly losses. Guidelines vary, but IV iron is typically recommended when oral supplements have failed, when ferritin is very low despite treatment, or when symptoms are severe enough to warrant rapid correction.

How Quickly IV Iron Works Compared to Oral

Across multiple clinical scenarios, including kidney disease, IBD, postpartum recovery, and cancer-related anemia, IV iron consistently provides a faster rise in hemoglobin and ferritin than oral supplements.¹⁴ The advantage is most pronounced in conditions where oral absorption is compromised or iron requirements are very high. In situations where the gut is healthy and the deficiency is mild, the end result at several months may be similar, though IV iron still gets there sooner.

That speed advantage has real consequences. A patient with debilitating fatigue, breathlessness, or restless legs can start feeling better within days to a couple of weeks after an infusion, whereas oral iron at standard doses may take two to three months to produce a noticeable change. One trial in iron-deficient blood donors found that both IV and oral iron significantly improved fatigue, sleep quality, restless legs symptoms, headaches, dizziness, and breathlessness, with no meaningful difference in clinical outcomes between routes, though that population had relatively uncomplicated deficiency.¹⁵

How Doctors Calculate the Dose

Unlike oral iron, where you simply take a daily pill, IV iron doses are usually calculated based on your body weight and how far your hemoglobin is from target. The most widely used approach is a version of the Ganzoni formula, which multiplies your weight in kilograms by the hemoglobin deficit and a constant, then adds an amount to replenish stores. In clinical studies, a modified version adds 500 mg to replete iron stores, though that extra 500 mg is sometimes omitted for patients whose TSAT is above 20% and ferritin above 50 ng/mL to avoid overloading someone who isn’t as depleted.¹⁶ In practice, total calculated doses often fall somewhere between 500 mg and 1,500 mg of elemental iron, delivered in one or more sessions depending on the product used.

Some newer formulations allow the full dose to be given in a single sitting, while older ones require it to be split across multiple visits. Your doctor’s choice of product and scheduling depends on local availability, insurance coverage, and your specific risk profile.

Safety and Side Effects

The concern that keeps some patients and doctors cautious about IV iron is the risk of allergic reactions. Modern formulations have made severe reactions rare, but they haven’t eliminated them. A large retrospective study found that the risk of anaphylaxis varied substantially by product. Iron dextran carried the highest risk at roughly 10 per 10,000 first administrations, followed by ferumoxytol at about 4 per 10,000. Iron sucrose and ferric carboxymaltose had the lowest rates, around 1 per 10,000.¹⁷ An earlier analysis using a different methodology produced broadly consistent findings: the anaphylaxis risk with dextran-based products was roughly two to three times higher than with non-dextran alternatives.¹⁸ Iron dextran has largely fallen out of favor in many countries as a result.

A less dramatic but more common side effect is hypophosphatemia, a drop in blood phosphate levels. This is particularly associated with ferric carboxymaltose (FCM), one of the most widely prescribed IV iron products. In head-to-head comparisons, severe hypophosphatemia occurred in roughly half of patients receiving FCM, compared with less than 1% of those receiving ferumoxytol.¹⁹ The PHOSPHARE trials found that about three-quarters of FCM-treated patients developed some degree of hypophosphatemia, versus 8% of those given ferric derisomaltose. Severe cases occurred in about 11% of the FCM group and none in the ferric derisomaltose group. Another study reported that the odds of developing hypophosphatemia after FCM were roughly 21 times higher than after iron isomaltoside.²⁰ Most cases resolve on their own, but repeated infusions of FCM in patients who need ongoing iron replacement can lead to prolonged low phosphate, which causes muscle weakness, bone pain, and fatigue that ironically mimics the symptoms of iron deficiency itself.

Infection Risk

Iron is a nutrient bacteria need to grow, and your body’s strategy of hiding iron away during infection, sometimes called nutritional immunity, is a fundamental part of the immune response. Flooding the bloodstream with iron during an active infection could theoretically feed the pathogen. A systematic review and meta-analysis found that IV iron was associated with a modestly increased risk of infection compared with oral iron or no iron, with about 16 additional infections per 1,000 people treated.²¹ The quality of this evidence was rated as moderate. In practice, most clinicians avoid giving IV iron during active, untreated infections, but the overall magnitude of the risk in stable patients has been small enough that it rarely overrides a clear indication for infusion.

IV Iron in Children and Adolescents

Pediatric iron infusions are less common than in adults, largely because children are usually tried on oral iron first and many respond well. When oral treatment fails or isn’t tolerated, IV iron can be given to children and adolescents. A cohort study of 144 patients under 18 who received ferric carboxymaltose after inadequate response to oral iron found that 85% reached the target ferritin of at least 30 µg/L after a single dose. The infusion was uneventful in 92% of patients, and no serious adverse events were recorded.²² The evidence base in pediatrics is thinner than in adults, and dosing is weight-based with more conservative protocols, but the available data suggest a safety profile consistent with what’s seen in older patients.

When You Might Get an Infusion Without Severe Anemia

It’s worth noting that iron infusions aren’t reserved for people with dangerously low hemoglobin. Iron deficiency without anemia, sometimes called “latent” or “pre-anemic” iron deficiency, can cause real symptoms: crushing fatigue, brain fog, restless legs at night, exercise intolerance, and hair thinning. Some patients with ferritin levels in the teens or twenties and normal hemoglobin feel dramatically better after iron repletion. The debate in these cases is usually about route rather than need. If you have no complicating condition and your gut works fine, most doctors will start you on oral iron and reassess in six to eight weeks. But if oral iron causes intolerable side effects (constipation, nausea, stomach cramps are common), if you have a condition that impairs absorption, or if you’ve already tried oral iron without improvement, an infusion becomes reasonable even without a diagnosis of frank anemia.

The pediatric data reinforce this point: in the study of 144 young patients given IV iron, the group included children with iron deficiency but without anemia who had simply failed oral therapy. Improvement in symptoms like fatigue was the treatment goal, not just correcting a number on a lab printout.

Choosing Between IV Iron Products

If your doctor recommends an infusion, the specific product matters more than many patients realize. The major options available in most countries include ferric carboxymaltose, ferric derisomaltose (also called iron isomaltoside), iron sucrose, ferumoxytol, and in some settings, iron dextran. They differ in how much iron can be delivered per session, how fast the infusion runs, and their side-effect profiles.

• Ferric carboxymaltose: allows high single-session doses (up to 750 mg in the US, up to 1,000 mg in Europe) but carries the highest risk of hypophosphatemia. Often preferred when convenience of fewer visits is a priority, but may not be ideal for patients needing repeated courses.
• Ferric derisomaltose: can deliver a full replacement dose (up to 2,000 mg) in a single visit with a much lower rate of hypophosphatemia. Increasingly favored where available.
• Iron sucrose: has one of the lowest anaphylaxis rates but requires multiple smaller infusions (typically 200 mg per session), meaning more clinic visits.
• Ferumoxytol: delivers up to 510 mg per session and works quickly, but carries a somewhat higher anaphylaxis risk than iron sucrose or FCM.
• Iron dextran: can deliver the full dose in one session but has the highest anaphylaxis rate and has largely been replaced by newer alternatives.

Insurance coverage, local formulary restrictions, and infusion center availability often dictate the choice as much as clinical preference. If you’re offered a product and have concerns about hypophosphatemia or reactions, it’s reasonable to ask your doctor whether an alternative is available.